Quantisnow Logo
Dashboard

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

$FOLD
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $FOLD alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $FOLD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FOLD

DatePrice TargetRatingAnalyst
12/13/2024$17.00 → $12.00Overweight → Equal-Weight
Morgan Stanley
9/6/2024$18.00Buy
Jefferies
5/30/2024$18.00Overweight
Wells Fargo
5/14/2024$13.00Neutral → Buy
Guggenheim
12/19/2023$15.00 → $20.00Equal-Weight → Overweight
Morgan Stanley
9/9/2022$14.00Equal-Weight
Morgan Stanley
4/13/2022$11.00Neutral
Goldman
2/24/2022$16.00 → $14.00Outperform
SVB Leerink
More analyst ratings

$FOLD
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

    PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ETLeerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

    2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

    PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicu

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FOLD
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FOLD
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FOLD
 SEC Filings

See more

$FOLD
 Leadership Updates

Live Leadership Updates

See more

  • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

    Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

    Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FOLD
 Financials

Live finance-specific insights

See more

  • Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

    2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

    PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicu

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

    Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. "The third quarter of the year was marke

    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FOLD
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more